US/UK/Canada

Share

Pick a time period -
Tags ( Active)

PrimECC studien färdigrekryterad

PrimECC® är en CE-märkt och patentskyddad produkt, som är utvecklad för att förbereda (priming på engelska) hjärtlungmaskiner inför öppen hjärtkirurgi. En tidigare ’proof of concept’ studie som gjorts med PrimECC® påvisar intressanta kliniska resultat. Den studie som nu färdigrekryterats har för avsikt att utöka den kliniska dokumentationen för PrimECC® och inkluderade totalt 80 patienter. Analys av resultaten kommer nu att påbörjas och den första publikationen från studien är beräknad till senare delen av 2017.Det sker flera hundratusen hjärtoperationer per år i världen då hjärtlungmaskin

Interim Report January – March 2017

CONTINUED GROWTH AND DIRECTED ISSUE OF 181 MSEKFIRST QUARTER 2017 (JAN - MAR) • Net sales of non-Durable goods in the quarter amounted to SEK 33.6 (29.1) million, corresponding to an increase of 16 percent in SEK. Sales of non-Durable goods increased by 11 percent in local currency. Net sales in the quarter amounted to SEK 37.5 (33.5) million, corresponding to an increase of 12 percent. The increase corresponds to 7 percent in local currency. The acquisition of Vivoline had a positive impact of SEK 0.9 million on sales.• Operating income before depreciation and amortization (EBITDA),

XVIVO Perfusion Interim report January – September 2016

CONTINUED GROWTH AND POSITIVE OPERATING CASH-FLOWTHIRD QUARTER 2016 (JUL – SEP) • Net sales in the quarter amounted to SEK 31.7 (26.6) million, corresponding to an increase of 19 percent. The acquisition of Vivoline had a positive impact of SEK 1.6 million on sales. Adjusted for this, growth amounted to 13 percent in SEK and 12 in local currency.• Operating income before depreciation and amortization (EBITDA) excluding items effecting comparability increased by 22 percent and amounted to SEK 5.4 (4.4) million, corresponding to an EBITDA margin of 17 percent. Items effecting

XVIVO Perfusion Interim report January – June 2016

ACQUISITION OF VIVOLINE STRENGTHENS XVIVO’S PRODUCT AND R&D PORTFOLIOSECOND QUARTER 2016 (APR – JUN) • Net sales in the quarter amounted to SEK 34.5 (29.1) million, corresponding to an increase of 18 percent. Net sales of non-Durable goods* in the quarter amounted to SEK 29.8 (27.4) million, corresponding to an increase of 9 percent in SEK and 11 percent in local currency.• Operating income before depreciation and amortization (EBITDA) excluding one-time expenses increased by 51 percent and amounted to SEK 6.9 (4.6) million, corresponding to an EBITDA margin of 20 percent. One-time

Extension of the acceptance period of XVIVO Perfusion’s public offer on Vivoline Medical has ended

The Offer is not made, and this press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by Swedish law.  XVIVO Perfusion AB (“XVIVO Perfusion”) announced on 18 April 2016 a recommended public offer to the holders of shares (“

Conference call on Interim Report

Invitation to attend XVIVO Perfusion’s conference call regarding the presentation of the Interim Report January – June 2016. The presentation will be held in English.Time: Friday, July 15, 2016 at 2.00 p.m. CET  Registration can preferably be done in advance under the following link: https://engage.vevent.com/rt/xvivoperfusion/index.jsp?seid=67  or shortly before time of the conference starts on:Sweden dial in number: +46 (0)8-503 364 34International dial in number: +44 (0) 1452 555566Conference name: XVIVO Perfusion, conference ID: 41101325  Participants from XVIVO

XVIVO Perfusion extends the acceptance period for the public offer on Vivoline Medical

The Offer is not made, and this press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by Swedish law.  XVIVO Perfusion AB (“XVIVO Perfusion”) announced on 18 April 2016 a recommended public offer to the holders of shares (“

Conference call regarding information on the offer made to Vivoline’s shareholders

Invitation to attend XVIVO Perfusion’s conference call regarding information on the offer made to Vivoline’s shareholders. The presentation will be held in Swedish.This press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by

XVIVO Perfusion published prospectus regarding the public offer to the holders of shares and warrants of series 2015/2016 in Vivoline Medical

The prospectus[1] regarding XVIVO Perfusion AB’s (publ) (”XVIVO Perfusion”) recommended public offer to the holders of shares (“Shares”) and warrants of series 2015/2016 (“Warrants”) in Vivoline Medical AB (“Vivoline”) to transfer all of their Shares and Warrants to XVIVO Perfusion (the “Offer”) has been approved by the Swedish Financial Supervisory Authority (the “SFSA”) and is now available on inter alia XVIVO Perfusion’s website.The Offer is not made, and this press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South

Settlement between XVIVO and Vivoline

XVIVO Perfusion AB (publ) initiated legal proceedings, claiming the right to three patents/patent applications owned by Vivoline Medical AB (publ) with regard to inventions made by Stig Steen. XVIVO Perfusion and Vivoline have now reached an agreement whereby, amongst other things, XVIVO Perfusion withdraws its claim at Lund District Court and compensates Vivoline for trial costs in the amount of approximately SEK 1.6 million. This sum will be charged to the first quarter of 2015. Through this agreement, the parties' differences in regard to the dispute have been definitively settled.

XVIVO Perfusion files lawsuit against Vivoline

XVIVO Perfusion is suing Vivoline to safeguard XVIVO Perfusion’s exclusive rights to Vivoline’s patents for three products invented by Professor Stig Steen.XVIVO Perfusion AB (publ) has today initiated legal proceedings against Vivoline Medical in order to safeguard the exclusive global unlimited rights that XVIVO Perfusion AB (publ) has to certain media developed by Professor Stig Steen for the evaluation and preservation of organs in connection with transplantation. XVIVO Perfusion’s own product STEEN Solution™ is not part of the dispute and is protected by a patent which has been

Clarification of XVIVO Perfusion’s rights to Professor Stig Steen’s media for the preservation and evaluation of organs

Due to the insufficient information that Vivoline Medical has distributed in a Memorandum (including supplementary information that was recently published) ahead of its planned new share issue and listing on AktieTorget, XVIVO Perfusion feels obliged to provide information on the exclusive global unlimited rights that XVIVO Perfusion has to certain media developed by Professor Stig Steen and Vivoline Medical for the evaluation and preservation of organs in connection with transplantation. Pursuant to the current agreement with Professor Stig Steen and Igelösa Life Science AB, XVIVO

There are no items matching the current filter
There are no more items matching the current filter
Back to top